Merck KGaA: The 350-Year-Old Family Company That Listed Without Losing Control

The oldest pharmaceutical and chemical company in the world is still run by the family that started it, and it trades on a public exchange. The mechanism is the German partnership limited by shares, a legal form that separates ownership economics from management control more decisively than any dual-class share structure. This case study belongs to the chemicals pillar of the Germany Company Stories hub and extends the family ownership and governance pillar.

How does the KGaA structure actually work?

The company has two classes of participant. General partners hold management authority and unlimited liability in the classical form, though in modern structures the general partner is itself a limited company owned by the family. Limited shareholders hold ordinary tradeable shares with dividend and residual rights but no ability to appoint or remove management.

The practical effect is that a takeover is impossible. An acquirer could purchase every listed share and still not control the company, because management authority sits with the general partner rather than with the shareholder meeting.

At Merck the family holds its interest through a family holding entity with a large majority of the total capital, alongside the general partner structure, which means control is doubly secured through both economics and legal form.

Several other large German companies use variants of the same form, and it is the German answer to a problem that other jurisdictions solve with dual-class shares: how to be publicly financed without being publicly controlled.

Why does a three-hundred-year-old company need public capital at all?

Because the businesses it operates require capital at a scale family reinvestment cannot fund. Pharmaceutical development, semiconductor materials and life science tools each demand sustained investment measured in billions, and acquisitions in these fields are large and periodic.

The company's three divisions are unusually well chosen. Healthcare provides research-driven pharmaceutical exposure. Life Science supplies the tools, reagents and process materials used by every biotechnology and pharmaceutical company, which is a picks-and-shovels position with recurring revenue. Electronics supplies specialty materials to semiconductor manufacturers.

That portfolio is diversified across cycles that do not correlate strongly, which is exactly what a family owner with a multi-generational horizon should want and what a public market frequently penalises as lack of focus.

The tension is visible in valuation. Conglomerate structures attract a discount, and Merck is a conglomerate held by a family that will not break it up because breaking it up would surrender the diversification that protects the family's wealth.

What does the Life Science division actually do?

It supplies the inputs and equipment used to research and manufacture biological products: reagents, chromatography media, filtration, cell culture materials and laboratory chemicals, sold to pharmaceutical companies, biotechnology firms and academic laboratories.

The business model is attractive for the same reason the equivalent industrial businesses are. Once a material is written into a validated manufacturing process, changing it requires regulatory requalification, so switching costs are extremely high and revenue is recurring.

This is the same moat structure described in the hidden champions analysis, operating at much larger scale. The customer's cost of a failure vastly exceeds any price saving from an alternative supplier.

The cyclicality that does exist comes from customer capital spending and from inventory cycles in biotechnology, which produced a sharp destocking correction across the sector after the pandemic ordering surge. That is a working capital cycle rather than a structural change in demand.

How does family control affect capital allocation?

It lengthens the horizon and slows the response. Large acquisitions at Merck have historically been financed conservatively and deleveraged deliberately over several years rather than refinanced opportunistically, which reduces returns in good markets and reduces risk in bad ones.

The family also imposes an implicit ceiling on leverage that a purely financial owner would not. That has kept the company out of the situations that damaged competitors, and it has meant declining to transactions that a more aggressive balance sheet could have won.

The pharmaceutical division illustrates the cost. Research-driven pharmaceuticals is a business where scale and portfolio breadth matter, and a mid-sized player with disciplined leverage cannot buy its way to the front rank. Merck's answer has been selective focus on specific therapeutic areas rather than breadth.

Whether that is prudence or timidity depends on the outcome, which is the recurring difficulty with evaluating patient capital: the same behaviour looks like discipline in a downturn and like missed opportunity in an expansion.

Is the structure sustainable across further generations?

It has been for more than three centuries, which is evidence but not proof. The mechanism is governance rather than luck: a formal family constitution, a family council, defined rules on who may work in the business, and a partnership structure that prevents individual heirs from selling control.

The practical challenge is the growing number of family members with economic interests and no operational role. Distributions must satisfy a widening group whose members have different liquidity needs, ages and risk tolerances, and disagreement among them is the classic failure mode.

Merck's answer includes a partial market for family interests within defined constraints, plus a professional management layer in which family members participate through governance rather than through executive roles.

The transferable point for any family group is that ownership rules must be written before they are needed. A family that negotiates its constitution during a dispute writes a bad one, which is the recurring finding in the succession analysis.

Why did the semiconductor materials business become strategically important?

Because advanced chipmaking consumes an extraordinary variety of high-purity specialty materials, and qualification of a material into a leading-edge process is a multi-year commitment that effectively locks in the supplier.

The economics resemble the industrial hidden champion model at large scale: small volumes, extreme purity requirements, very high switching costs and customers whose cost of a defect is measured in ruined wafer lots rather than in material price.

The strategic significance grew as semiconductor supply chains became a geopolitical concern. A European supplier of critical process materials occupies a position that governments now consider strategically relevant, with the associated benefits of industrial policy support and the associated constraints on customers and ownership.

The demand profile is also more cyclical than pharmaceuticals, tied to semiconductor capital spending and fab utilisation, which adds volatility to a group otherwise structured for stability.

What happens to a KGaA in a crisis?

It is more resilient and less adaptable. Because control cannot be seized, the company cannot be forced into a distressed sale or broken up by an opportunistic acquirer during a downturn, which is genuine protection.

The cost appears if management itself is the problem. Where a listed company would face investor pressure, board change or a takeover approach, a KGaA relies entirely on the family and the supervisory body recognising the issue and acting.

The historical record for the large German family structures is reasonably good, largely because the families involved have institutionalised governance rather than relying on individual judgement. The failures in this category tend to involve smaller structures without formal family constitutions.

For an investor, the practical assessment is qualitative: examine the family governance framework, the independence of the supervisory body and the track record of management appointments, because those are the only correction mechanisms that exist.

How should investors approach a KGaA valuation?

By accepting the governance discount as permanent and focusing on operating performance. Attempting to model a scenario in which the structure changes wastes analytical effort, because no external mechanism can force it.

The practical approach is to value each division on sector comparables, apply a holding discount reflecting both conglomerate structure and governance, and then test whether the operating businesses justify the price after that adjustment.

The upside case in these structures generally comes from operational execution or from voluntary portfolio action by the controlling family, not from governance reform. Where a family has historically shown willingness to reshape the portfolio, the discount is arguably too wide; where it has not, the discount is rational.

The risk case is concentration in a single division that deteriorates while the family declines to act, since there is no mechanism to accelerate the decision.

How does Merck decide between its three divisions for capital?

By return profile and by capability fit rather than by growth alone. Healthcare consumes research capital with long payback and binary outcomes. Life Science requires steady capacity and acquisition capital in a fragmented market. Electronics needs cyclical capacity investment tied to semiconductor capital spending.

The family owner's preference for diversification means the group is unlikely to concentrate capital in one division even when a single division offers the highest expected return, because portfolio stability is itself an objective.

That is defensible for a controlling owner with a multi-generational horizon and it explains the persistent valuation discount, since a public shareholder can diversify far more cheaply by owning three separate companies.

What is the record on large acquisitions?

Mixed, and the pattern is instructive. Acquisitions that extended the Life Science position into adjacent bioprocessing and laboratory materials have generally performed well, because the acquired businesses shared customers, channel and regulatory characteristics with the existing base.

Acquisitions in electronics materials broadened the portfolio into a market with different cyclicality and a different customer set, and those transactions took longer to justify. Attempts to add scale in pharmaceuticals have been constrained by the leverage discipline the family imposes.

The generalisable finding matches the conglomerate analysis: acquisitions that extend an existing capability outperform acquisitions that add a new one, and the difference is visible in integration cost within the first two years.

Frequently Asked Questions